文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

心力衰竭注册研究与临床试验在患者特征方面的异同。

Similarities and differences in patient characteristics between heart failure registries versus clinical trials.

作者信息

Sharma Abhinav, Ezekowitz Justin A

机构信息

University of Alberta, Edmonton, Canada.

出版信息

Curr Heart Fail Rep. 2013 Dec;10(4):373-9. doi: 10.1007/s11897-013-0152-x.


DOI:10.1007/s11897-013-0152-x
PMID:23943315
Abstract

Acute and chronic heart failure results in significant morbidity and mortality to patients and is a major concern for the healthcare systems. Various randomized controlled trials have demonstrated an improvement in morbidity and mortality for patients with heart failure. However, the findings of these trials are often applicable to a limited population. Several large-scale registries are now shedding insight as to the treatment, outcomes, and follow-up of patients in a real-life clinical setting. The objective of this review is to examine some of the heart failure therapies, such as cardiac resynchronization therapy, implantable cardioverter defibrillators and medications, in the context of randomized trials versus clinical registries. This review will also identify how registries are improving patient outcomes and how they are uncovering differences and gaps in treatment in non-randomized trial settings.

摘要

急慢性心力衰竭会给患者带来显著的发病率和死亡率,是医疗系统主要关注的问题。各种随机对照试验已证明可改善心力衰竭患者的发病率和死亡率。然而,这些试验的结果往往仅适用于有限的人群。现在,一些大规模登记研究正在揭示现实临床环境中患者的治疗、预后及随访情况。本综述的目的是在随机试验与临床登记研究的背景下,考察一些心力衰竭治疗方法,如心脏再同步治疗、植入式心脏复律除颤器及药物治疗。本综述还将确定登记研究如何改善患者预后,以及它们如何在非随机试验环境中发现治疗方面的差异和差距。

相似文献

[1]
Similarities and differences in patient characteristics between heart failure registries versus clinical trials.

Curr Heart Fail Rep. 2013-12

[2]
Lessons Learned and Insights Gained in the Design, Analysis, and Outcomes of the COMPANION Trial.

JACC Heart Fail. 2016-6-8

[3]
Efficacy of Pharmacologic and Cardiac Implantable Electronic Device Therapies in Patients With Heart Failure and Reduced Ejection Fraction: A Systematic Review and Network Meta-Analysis.

Circ Arrhythm Electrophysiol. 2019-6-4

[4]
The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries.

J Am Coll Cardiol. 2014-2-5

[5]
[Cardioverter-defibrillator (ICD) and resynchronization in every patient with cardiac failure].

Dtsch Med Wochenschr. 2006-10-13

[6]
Use of evidence-based therapy and survival in heart failure in Sweden 2003-2012.

Eur J Heart Fail. 2016-2-11

[7]
ICDs Are Still an Effective Therapy to Prevent Sudden Cardiac Death in Heart Failure.

JACC Heart Fail. 2019-10

[8]
Baseline Functional Class and Therapeutic Efficacy of Common Heart Failure Interventions: A Systematic Review and Meta-analysis.

Can J Cardiol. 2015-1-7

[9]
Beta-blocker, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, nitrate-hydralazine, diuretics, aldosterone antagonist, ivabradine, devices and digoxin (BANDAID(2) ): an evidence-based mnemonic for the treatment of systolic heart failure.

Intern Med J. 2016-6

[10]
Neurohormonal Antagonists Are Preferred to an Implantable Cardioverter-Defibrillator in Preventing Sudden Death in Heart Failure.

JACC Heart Fail. 2019-10

引用本文的文献

[1]
Improving clinical trial efficiency using a machine learning-based risk score to enrich study populations.

Eur J Heart Fail. 2022-8

[2]
Mortality trends in an ambulatory multidisciplinary heart failure unit from 2001 to 2018.

Sci Rep. 2021-1-12

[3]
Determining the Suitability of Registries for Embedding Clinical Trials in the United States: A Project of the Clinical Trials Transformation Initiative.

Ther Innov Regul Sci. 2021-1

[4]
B-type natriuretic peptide-guided therapy for heart failure (HF): a systematic review and meta-analysis of individual participant data (IPD) and aggregate data.

Syst Rev. 2018-7-31

[5]
The treatment gap in patients with chronic systolic heart failure: a systematic review of evidence-based prescribing in practice.

Heart Fail Rev. 2016-11

本文引用的文献

[1]
Factors associated with improvement in utilization of cardiac resynchronization therapy in eligible heart failure patients: findings from IMPROVE HF.

Pacing Clin Electrophysiol. 2013-4

[2]
Randomized trials published in higher vs. lower impact journals differ in design, conduct, and analysis.

J Clin Epidemiol. 2013-3

[3]
Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials.

JAMA. 2013-1-2

[4]
Follow-up of patients with new cardiovascular implantable electronic devices: are experts' recommendations implemented in routine clinical practice?

Circ Arrhythm Electrophysiol. 2012-12-23

[5]
Cost-effectiveness of cardiac resynchronisation therapy.

Heart. 2012-12

[6]
The 2012 Canadian Cardiovascular Society heart failure management guidelines update: focus on acute and chronic heart failure.

Can J Cardiol. 2012-11-30

[7]
Implantable cardioverter defibrillators. Prophylactic use: an evidence-based analysis.

Ont Health Technol Assess Ser. 2005

[8]
Acute heart failure: perspectives from a randomized trial and a simultaneous registry.

Circ Heart Fail. 2012-10-2

[9]
Statins in heart failure: the paradox between large randomized clinical trials and real life.

Mayo Clin Proc. 2012-6

[10]
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC.

Eur Heart J. 2012-7

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索